Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 1483 results for patients and public

  1. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development Reference number: GID-TA11404 Expected publication date: TBC

  2. Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)

    This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.

  3. Air pollution: outdoor air quality and health (QS181)

    This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.

  4. Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]

    In development Reference number: GID-TA11333 Expected publication date: TBC

  5. Air pollution: outdoor air quality and health (NG70)

    This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.

  6. Coexisting severe mental illness and substance misuse (QS188)

    This quality standard covers the assessment, management and care provided for people aged 14 and over who have coexisting severe mental illness and substance misuse. It describes high-quality care in priority areas for improvement.

  7. Sexually transmitted infections: condom distribution schemes (NG68)

    This guideline covers condom distribution schemes. The aim is to reduce the risk of sexually transmitted infections (STIs). In addition, these schemes can provide a good introduction to broader sexual and reproductive health services, especially for younger people, and help prevent unplanned pregnancies.

  8. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date:  10 June 2026

  9. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]

    Awaiting development Reference number: GID-TA11978 Expected publication date: TBC

  10. Healthcare-associated infections (QS113)

    This quality standard covers preventing and controlling infections in hospitals and other secondary care settings that develop because of treatment or from being in a healthcare setting (healthcare-associated infections). It includes monitoring, responsibilities, and policies and procedures in secondary care organisations to reduce the risk of infection in patients, staff and visitors. It describes high-quality care in priority areas for improvement.

  11. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)

    This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.

  12. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  10 June 2026

  13. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  14 July 2026

  14. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date: TBC

  15. Atogepant for treating migraine [ID6615]

    In development Reference number: GID-TA11817 Expected publication date:  09 July 2026